课题基金 / 基金详情

Development of Molecularly Targeted Ultrasound Contrast Agents for Prostate Cancer Imaging using Bioorthogonal Chemistry

Development of Molecularly Targeted Ultrasound Contrast Agents for Prostate Cancer Imaging using Bioorthogonal Chemistry
利用生物正交化学开发用于前列腺癌成像的分子靶向超声造影剂
批准号:
336372
负责人:
Valliant John F
金额:
$19.03万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2015
资助国家:
加拿大
项目状态:
已结题
起止时间:
2015-10-01 至 2018-10-01

项目摘要

项目成果

Valliant John F的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Current imaging and biopsy methods for the detection of prostate cancer have major limitations that impact patient outcomes and can lead to unnecessary treatments. These include the use of ineffective therapies, or unnecessary and life-altering side effec
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Getting to the heart of hard-to-treat cancers: Anti-CD133 theranostics for molecular imaging and treatment of GBM
  • 批准号:
    403300
  • 项目类别:
    Operating Grants
  • 资助金额:
    $62.7万
  • 财政年份:
    2019
  • 负责人:
    Valliant John F
  • 依托单位:
The formulation and clinical testing of I-123 Iodohippuran as an alternative to Tc-99m MAG3 for assessment of renal function in patients with kidney disease
  • 批准号:
    191791
  • 项目类别:
    Operating Grants
  • 资助金额:
    $13.8万
  • 财政年份:
    2009
  • 负责人:
    Valliant John F
  • 依托单位:
海外基金